SS CELL PHONE CENTERBusiness Directories,Company Directories

Company Name: Corporate Name:	SS CELL PHONE CENTER
Company Title:
Company Description:
Keywords to Search:
Company Address:	6295 Mississauga Rd,MISSISSAUGA,ON,Canada
ZIP Code: Postal Code:	L5N
Telephone Number:	9058138623
Fax Number:	9058582781
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	0
USA SIC Description:	Accountants
Number of Employees:
Sales Amount:	$500,000 to $1 million
Credit History: Credit Report:	Unknown
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
SSB HOSE LTD
SSB MANAGEMENT & FINANCIAL SERVI
SSAUGA BARBER SHOP

Next company profile:
SS CELL PHONE CENTRE
SS CELL CENTER
SS ACCOUNTING SERVICES

Company News:

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 . . .
Background: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known
Triple-hormone receptor agonist retatrutide significantly improves . . .
In a phase 2 study in participants who have obesity or overweight but not type 2 diabetes (T2D) (n=338), retatrutide (RETA), an agonist of GIP, GLP-1 and glucagon receptors, reduced body weight, glycated hemoglobin, triglycerides (TG), LDL-C and VLDL-C
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
In this trial involving participants with obesity, 48 weeks of treatment with retatrutide, an agonist of the GIP, GLP-1, and GCG receptors, resulted in substantial reductions in body weight
Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss
At 48 weeks, the average percentage weight loss was about 24% in the 12-mg dose retatrutide group
Triple hormone receptor agonist retatrutide for metabolic . . . - Nature
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors A 48-week phase 2 obesity study demonstrated
TRIPLE HORMONE RECEPTOR AGONIST RETATRUTIDE RESOLVES STEATOSIS . . . - AASLD
Background: Retatrutide (RETA; LY3437943) is a novel triple agonist of the GIP, GLP-1 and glucagon receptors under investigation for obesity treatment A 48-week phase 2 obesity study demonstrated weight loss of −22 8% and −24 2% with RETA 8 and 12 mg
American Diabetes Association Highlights Novel Agent Retatrutide which . . .
The Triple–Hormone-Receptor Agonist Retatrutide for Obesity Phase 2 Trial was designed to look at the efficacy and safety of retatrutide for the treatment of obesity and comes at a time when it is projected that by 2030, nearly 1 in 2 Americans will have obesity
Retatrutide (GLP-3) Next-Gen Triple-Agonist for Obesity Diabetes
A deep dive into retatrutide, a triple-agonist targeting GLP-1, GIP, and glucagon receptors This article analyzes the clinical trial data on its significant weight loss effects and metabolic benefits, explaining its mechanism and comparing it to other leading peptide therapeutics
Phase 2 trial results demonstrate benefits of retatrutide in obesity . . .
Findings from two related phase 2 clinical trials looking at the novel triple-hormone receptor agonist retatrutide were presented during a late-breaking symposium at the 83rd Scientific Sessions